ORTX News and Press, Orchard Therapeutics plc From 02/04/22

Buying Penny Stocks Today? Here’s What You Need to Know Yesterday, we witnessed many penny stocks and blue chips fall substantially. This was led by Meta, the parent company of Facebook, dropping in value by more than 26%. As a result, the tech heavy NASDAQ, dropped by over 3.7% ...

Orchard Therapeutics (NASDAQ:ORTX) is trading ~8% higher in the pre-market on Friday after the company announced an agreement with the National Health Service (NHS) to allow access to its stem cell gene therapy Libmeldy for eligible children. Libmeldy, also known as atidarsagene aut...

Snap (NYSE:SNAP) +40% on Q4 results. Bill.com Holdings (NYSE:BILL) +23% on Q2 results. Sphere 3D (NASDAQ:ANY) +16% on purchase of 60K Numiner NM440 BTC Miners. Unity Software (NYSE:U) +14% on Q4 results. Standard Lithium (NYSE:SLI) +12% set to rebound from short seller's s...

First-ever lentiviral hematopoietic stem cell gene therapy approved for reimbursement by NHS England Two children with early-onset MLD recently treated commercially with Libmeldy in Germany and France A third eligible patient identified through partnership in Middle East...

Administration of one-time hematopoietic stem cell (HSC) gene therapy resulted in sustained, clinically meaningful benefits by preserving cognitive function and motor development in most patients 90% overall survival with up to 7.5 years of follow-up (median 3.2 years) in 29 pat...

Launch Momentum Building for Libmeldy ® in Europe with Health Technology Assessments Progressing Favorably and Treatment Underway for Multiple Commercial Patients Initiating U.S. BLA Submission for OTL-200 as Early as Year End 2022; Constructive CMC Meeting with FDA Sup...

BOSTON and LONDON, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the company is scheduled to present at the virtual 40th Annual J.P. Morgan Healthcare Conference on Thursday January 13, 2022, at 9:00 a.m. ET. ...

Gainers: MedAvail (NASDAQ:MDVL) +17%, Altamira Therapeutics (NASDAQ:CYTO) +17%, Orchard Therapeutics (NASDAQ:ORTX) +10%,Biofrontera (NASDAQ:BFRI) +9%, XORTX Therapeutics (NASDAQ:XRTX) +7%. Losers: Chembio Diagnostics (NASDAQ:CEMI) -16%, Gamida Cell (NAS...

3 Top Penny Stocks to Watch Under $3 Right Now As the year comes to an end, we are still in the midst of a Santa Claus rally for penny stocks and blue chips. While the rally has calmed down with the stock market flat during today’s trading so far, the end of the year has been a s...

Cantor Fitzgerald analyst Pete Stavropoulos assumed coverage of Orchard Therapeutics (NASDAQ:ORTX) with an Overweight rating with a price target (PT) of $9, down from $12. Shares up 10% premarket $1.19. PT of $9 implies a premium of ~656.3% to the last close. Orchard is de...